ES2273517T3 - Compuestos de bencimidazol que son antagonistas del receptor de vitronectina. - Google Patents

Compuestos de bencimidazol que son antagonistas del receptor de vitronectina. Download PDF

Info

Publication number
ES2273517T3
ES2273517T3 ES99962691T ES99962691T ES2273517T3 ES 2273517 T3 ES2273517 T3 ES 2273517T3 ES 99962691 T ES99962691 T ES 99962691T ES 99962691 T ES99962691 T ES 99962691T ES 2273517 T3 ES2273517 T3 ES 2273517T3
Authority
ES
Spain
Prior art keywords
cycloalkyl
alkyl
baselineskip
aryl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99962691T
Other languages
English (en)
Spanish (es)
Inventor
Bernard R. Neustadt
Elizabeth M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2273517T3 publication Critical patent/ES2273517T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES99962691T 1998-11-30 1999-11-29 Compuestos de bencimidazol que son antagonistas del receptor de vitronectina. Expired - Lifetime ES2273517T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20161198A 1998-11-30 1998-11-30
US201611 1998-11-30

Publications (1)

Publication Number Publication Date
ES2273517T3 true ES2273517T3 (es) 2007-05-01

Family

ID=22746536

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99962691T Expired - Lifetime ES2273517T3 (es) 1998-11-30 1999-11-29 Compuestos de bencimidazol que son antagonistas del receptor de vitronectina.

Country Status (12)

Country Link
EP (1) EP1135374B9 (https=)
JP (1) JP4480117B2 (https=)
CN (1) CN1161340C (https=)
AR (1) AR021427A1 (https=)
AT (1) ATE338751T1 (https=)
AU (1) AU1908400A (https=)
CA (1) CA2353063C (https=)
CO (1) CO5140112A1 (https=)
DE (1) DE69933135T2 (https=)
ES (1) ES2273517T3 (https=)
PE (1) PE20001427A1 (https=)
WO (1) WO2000032578A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061552A1 (en) * 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
WO2000069810A1 (en) * 1999-05-17 2000-11-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP2164958B1 (en) 2007-06-07 2014-08-13 Novozymes A/S Method of preparing a dough-based product
DK2595488T3 (da) 2010-07-21 2020-02-24 Novozymes As Fremgangsmåde til fremstilling af et bagt produkt med antiældningsamylase og peptidase
AU2015217788B2 (en) 2014-02-11 2019-06-27 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Benzimidazol-2-amines as mIDH1 inhibitors
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
CN104694290A (zh) * 2014-05-07 2015-06-10 宁波职业技术学院 一种洗脚皂
CN107108522B (zh) 2014-10-23 2020-12-01 德国癌症研究中心 作为mIDH1抑制剂的苯并咪唑-2-胺
EP3209660B1 (en) 2014-10-23 2020-06-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
WO2016198322A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
WO2017009325A1 (en) 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
US20230106032A1 (en) 2020-03-06 2023-04-06 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
EP0767792A4 (en) * 1994-06-29 2002-11-20 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
CN1161340C (zh) 2004-08-11
DE69933135D1 (de) 2006-10-19
ATE338751T1 (de) 2006-09-15
CA2353063C (en) 2009-06-16
EP1135374B1 (en) 2006-09-06
AR021427A1 (es) 2002-07-17
WO2000032578A8 (en) 2002-02-07
AU1908400A (en) 2000-06-19
DE69933135T2 (de) 2007-08-09
PE20001427A1 (es) 2000-12-18
JP4480117B2 (ja) 2010-06-16
JP2002531441A (ja) 2002-09-24
CA2353063A1 (en) 2000-06-08
EP1135374A1 (en) 2001-09-26
WO2000032578A1 (en) 2000-06-08
EP1135374B9 (en) 2007-02-21
CN1333755A (zh) 2002-01-30
CO5140112A1 (es) 2002-03-22

Similar Documents

Publication Publication Date Title
ES2273517T3 (es) Compuestos de bencimidazol que son antagonistas del receptor de vitronectina.
ES2325071T3 (es) Derivados del acido indol-oxo-acetilaminoacetico sustituido como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
EP1009758A1 (en) Meta-benzamidine derivatives as serine protease inhibitors
ES2227500T3 (es) (s)-4-amino.5-cloro-2-metoxi-n-(1-(1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil)-4-piperidinil) benzamina para el tratamaiento de desordenes de la motilidad gastrointestinal.
JP2001512134A (ja) Ｖｌａ−４仲介性白血球付着を阻害する置換フェニルアラニン型化合物
JP2001512138A (ja) Ｖｌａ−４が介在する白血球付着を阻害するベンジル化合物
JP2001512139A (ja) Ｖｌａ−４が介在する白血球接着を阻害するスルホニル化ジペプチド化合物
JP2001512135A (ja) Ｖｌａ−４によって媒介された白血球接着を阻害するジペプチドおよび関連化合物
JP2001512136A (ja) Ｖｌａ−４により仲介される白血球接着を抑制する化合物
RS50712B (sr) Triamid-supstituisani indoli, benzofurani i benzotiofeni kao inhibitori mikrozomalnog triglicerid transfer proteina (mtp) i/ili sekrecije apolipoproteina b (apo b)
PT101027A (pt) Peptideos, processo para a sua preparacao e sua utilizacao como compostos farmaceuticos
JPH11504015A (ja) メタロプロテアーゼおよびｔｎｆ阻害剤としての新規なヒドロキサム酸およびアミノ−カルボキシレート化合物
WO2023144379A1 (en) High-affinity ligands of fibroblast activation protein for targeted delivery applications
HRP20000574A2 (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
JPH11504320A (ja) メタロプロテアーゼ阻害剤としてのヒドロキサム酸およびカルボン酸
US7220781B2 (en) Meta-benzamidine derivatives as serine protease inhibitors
JP2002535304A (ja) Ｖａｌ−４により媒介される白血球接着を阻害する多環式化合物
US6372719B1 (en) ανβ3 integrin antagonists in combination with chemotherapeutic agents
KR19980702358A (ko) 엔도텔린 길항제로서의 벤조티아진 디옥사이드
CN101817769B (zh) 脲基类肽氨肽酶n抑制剂及其应用
CA3024071C (en) Libraries of diverse macrocyclic compounds and methods of making and using the same
JP2002535316A (ja) Ｖｌａ−４により媒介される白血球接着を阻害する縮合環へテロアリールおよび複素環式化合物
US6204282B1 (en) Benzimidazole compounds that are vitronectin receptor antagonists
WO1992018488A1 (en) Novel oxazinone derivative
JP2002535341A (ja) Ｖｌａ−４により媒介される白血球接着を阻害するピログルタミン酸誘導体および関連化合物